HOME > ARCHIVE

ARCHIVE

BUSINESS NEWS IN BRIEF

April 17, 2006
GENERIC NEWS IN BRIEF

April 17, 2006
Council to Collect Evidence on Pediatric Use of 5 Drugs

April 17, 2006
Ordinance Issued on Designation of Vaccines as Orphan Drugs

April 17, 2006
REGULATORY NEWS IN BRIEF

April 17, 2006
BOOK

April 17, 2006
EPS Establishes Subsidiary to Support Clin. Trials in Asia

April 17, 2006
BUSINESS NEWS IN BRIEF

April 10, 2006
JMA

April 10, 2006
FY2006 Budget Proposal Approved

April 10, 2006
39 of World's 99 Top-Selling Drugs Unapproved in Japan: Mr Wolf of PhRMA

April 10, 2006
Korosho to Gear Up Steps to Eliminate Provisional Delivery

April 10, 2006
Economist Conferences: 5th Roundtable on Healthcare Reform in Japan

April 10, 2006
REGULATORY NEWS IN BRIEF

April 10, 2006
Daiichi Sankyo Selects 5 Top-Priority Projects

April 10, 2006
Ono, Medarex in Collaboration to Develop Antibody Therapeutics

April 10, 2006
R&D NEWS IN BRIEF

April 10, 2006
NEW BOOK

April 10, 2006
SEMINAR

April 10, 2006
Growing Need for Generics with High Added Value: Prof. Ueno

April 10, 2006

ページ

Chuikyo Debate on FY2026 Drug Pricing Reform

Chuikyo OKs New CEA Handling, with Third-Party Verification Ahead

Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…

COMMENTARY

Are Technical Discussions Enough for Japan’s CEA System?

By Ken Yoshino

Japan is finally launching technical discussions on its cost-effectiveness assessment (CEA) system. A health ministry-funded research group is set to…

COLUMN

The Patient North Star: How Gilead Japan Redefined Innovation

By Philip Carrigan

In the complex landscape of the Japanese pharmaceutical market, the “status quo” is often the safest harbor. But for leaders like Kennet Brysting, former president of Gilead Japan, the status quo is the most dangerous place to stay.Innovation in Japan…